Biologic Therapy & Therapeutic Drug Monitoring

Certolizumab is the anti-TNF of choice in the third trimester of pregnancy — negligible placental transfer means infant cord-blood levels are undetectable and live vaccination schedule is unchanged.

Episodic anti-TNF dosing drives immunogenicity and loss of response — ACCENT-I established that scheduled maintenance is the only acceptable strategy. Never give "as needed" anti-TNF.

Missed latent TB reactivation is the #1 preventable anti-TNF complication in Saudi Arabia. Do NOT skip QuantiFERON even if CXR is clean — BCG vaccination makes TST unreliable.

If HSTCL risk concerns preclude thiopurine in young males, low-dose MTX 15 mg/week SC is a reasonable combination partner — reduces anti-drug antibody formation without the HSTCL signal.

Class-switch between anti-TNFs fails ~50% of the time because anti-drug antibodies are class-specific. If TDM confirms antibody-driven LOR, switch within class; if mechanistic with adequate trough, switch out of class.

Vedolizumab onset is slow in CD — if patient is steroid-dependent, bridge with a steroid taper over 10-14 weeks rather than expecting rapid response.

Ustekinumab is a strong choice for CD patients with comorbid psoriasis — single-agent management of both diseases without stacking therapies.

Risankizumab IV induction requires 600 mg at weeks 0/4/8 then SC 360 mg q8w — confirm infusion chair capacity before initiating.

Document the specific reason for biologic selection (severity, fistula, pregnancy plan, comorbidity) — this supports MOH/insurance prior authorization and defends the choice at audit.

Document the brand/biosimilar name with each administration — adverse event attribution and payer reimbursement depend on precise product identification.

Know your reference lab assay — interpreting "antibody positive" differs between drug-sensitive and drug-tolerant methods and can change clinical decisions.

The single most cost-effective TDM moment is end-of-induction: week 14 for IFX and week 4 for ADA. Do this routinely in every patient.

NEVER switch therapy based on TDM alone without confirming active inflammation — symptoms may be functional overlap, bile salt diarrhea, SIBO, or stricture.

At KFSHRC/KAMC schedule TDM labs on the morning of infusion day before the infusion runs — this captures true trough and batches blood draws.

Before calling LOR, ensure the patient actually received the drug — 10-15% of real-world "non-responders" had missed doses or wrong injection technique.

A steroid taper that reveals persistent symptoms with a normal endoscopy usually means functional overlap — send to psychology or dietetics, do not escalate biologic.

VEGA-like combination biologic therapy is investigational outside formal trials in Saudi Arabia — obtain MOH IRB and payer clearance before initiating.

LIR!C showed laparoscopic ileocecal resection in limited CD equivalent to infliximab at 1 year with better QoL at 5 years — consider surgery-first in discrete ileocecal disease.

If HSTCL risk concerns preclude thiopurine, low-dose MTX 15 mg/week SC is a reasonable combination partner — COMMIT was negative in monotherapy but combination supportive.

GEMINI-2 CD onset is slower — when expectation is fast relief, bridge with steroid taper or consider IFX/ustekinumab.

When writing MOH prior authorizations for biologic selection, quote VARSITY for UC vedolizumab and SEQUENCE for CD risankizumab post-TNF — payer committees recognize these names.

Combination biologic therapy remains investigational and expensive — reserve for severe refractory disease within an MDT framework and IRB-approved protocols.